Avecia Group

Nitto Avecia is a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide-based therapeutics. The company provides a comprehensive range of services from pre-clinical development through commercial-scale production. Their expertise covers various modalities including antisense oligonucleotides, siRNA, and aptamers. Following its acquisition by Nitto Denko in 2011, the company has expanded its capabilities to include drug delivery technologies and analytical services. Nitto Avecia operates several state-of-the-art facilities in the United States, supporting the global pharmaceutical and biotechnology industries.